Working With Cyprotex
Cyprotex recognizes the importance of excellent customer service in gaining repeat business. More than 70% of customers return to Cyprotex for a second round of services. Each of our customers is assigned a dedicated and highly experienced Project Manager who manages the conduct of the services being performed for the customers and can also assist with study design and data interpretation. Often this involves Cyprotex being part of the customer’s project team meetings helping to make key decisions on future screening strategies.
We understand that the quality of the data delivered to our customers is extremely important as data may be required for regulatory submission or for making key decisions on whether to take molecules forward into development. Cyprotex has its own Quality Assurance Policy in place. Quality Procedures include staff training and supervision, Standard Operating Procedures, equipment validation and calibration, data recording and retention. These Quality Procedures are strictly followed to deliver robust and scientifically valid data to our clients.
- Speed: Speeding up the time in which a drug reaches the market can dramatically reduce R&D costs during the drug discovery and development stages. Cyprotex offer rapid turnaround time with data for the majority of Cyprotex standard screens returned within 5-10 working days.
- Price: Cyprotex have developed automated systems which are highly efficient and allow us to keep our costs lower. Our pricing is highly competitive and provides considerable value for our customers.
- Confidentiality: Cyprotex does not in any circumstances disclose confidential information about its past, current or prospective customers outside the Company. This includes, without limitation, customer names, scientific information or data, pricing or financial information.
Improved Healthcare
The pharmaceutical industry is one of Cyprotex’s key customer markets. Cyprotex has developed its own high throughput systems to screen potential new drugs more efficiently and more rapidly – speeding up the time it takes for the drug discovery process and reducing costs for our customers.
Additionally, Cyprotex invests in many R&D projects. Many of these are focused in the field of in vitro toxicology where Cyprotex is helping to develop more clinically relevant models. The ultimate outcome of our research is to bring safer drugs to the market with the best chance of clinical success. Cyprotex is currently involved in the CiPA initiative where we play an active role in the evaluation of new testing methods for cardiac safety.
Reduction in Animal Testing
Ethical concerns over animal testing are growing. Within the cosmetics industry this has led to a ban on animal testing for any new cosmetic product or their ingredients. For new pharmaceuticals, preclinical toxicity testing in animals is still a requirement of the regulatory authorities due to the risk to human health. Cyprotex focuses its screening services and research activities on in vitro and in silico methods believing that these technologies will help to reduce and replace animal testing in the future.
Suppliers & Partners
Cyprotex expects all suppliers and partners to work towards and uphold the highest ethical and moral standards. The company will, if appropriate, consider the ethical record of potential new suppliers before entering into any agreement. The company reserve the right to withdraw from any agreement or other arrangement with any supplier or partner who is found to have acted in contravention of the spirit or principles of our own ethical policy.
More details on our ethical policy and code of conduct can be found here.
Contact Our Experts
